C-7UTSEndogena Therapeutics
endogenous regeneration, small molecules, stem/progenitor cells
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7UTS
C-7UTSC-7UTSendogenous regeneration, small molecules, stem/progenitor cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Endogena Therapeutics endogenous regeneration, small molecules, stem/progenitor cells
Endogena Therapeutics is a clinical-stage biotech company developing endogenous regenerative medicines for degenerative diseases related to aging and genetic disorders. Its discovery approach uses small molecules to selectively regulate endogenous adult stem and progenitor cells for controlled tissue repair. The company’s most advanced programs target degenerative eye diseases, including retinitis pigmentosa and age-related macular degeneration, with an additional program in idiopathic pulmonary fibrosis.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Endogena Therapeutics — Translational · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic